Canakinumab in Patients With COVID-19 and Type 2 Diabetes
Status:
Completed
Trial end date:
2021-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether Canakinumab has beneficial effects on
patients with Type 2 diabetes mellitus and coronavirus disease 19 (COVID19).